<DOC>
	<DOCNO>NCT00071968</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , CCI-779 , work different way stop tumor cell divide stop grow die . Giving CCI-779 surgery may shrink tumor remove . PURPOSE : This randomized phase II trial study well CCI-779 work treat patient undergo radical prostatectomy newly diagnose prostate cancer high risk relapse .</brief_summary>
	<brief_title>Neoadjuvant CCI-779 Followed By Radical Prostatectomy Treating Patients With Newly Diagnosed Prostate Cancer Who Have High Risk Relapse</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effect oral CCI-779 change phosphorylation state protein mammalian target rapamycin ( mTOR ) signal pathway tumor tissue patient newly diagnose prostate cancer undergo radical prostatectomy . - Determine effect drug change p70S6 kinase activity , phosphorylation state mTOR pathway protein , global target gene expression pattern peripheral blood mononuclear cell ( PBMCs ) patient . Secondary - Determine effect drug global target gene expression pattern patient . - Identify pharmacodynamic/pharmacogenomic surrogate marker drug tumor tissue PBMCs determine blood may use surrogate tissue source biomarkers drug activity tumor patient . - Determine , preliminarily , potential antitumor effect drug patient . - Determine pharmacokinetics drug patient . - Correlate phosphatase tensin homolog ( PTEN ) gene status pharmacodynamic/pharmacogenomic effect drug patient . - Determine effect drug change protein expression pattern plasma patient . OUTLINE : This randomize , open-label , multicenter study . Patients randomize 1 3 treatment arm . Patients randomized arm III stratify accord tumor expression phosphatase tensin homolog ( PTEN ) gene mutation ( negative v positive ) . - Arm I : Patients receive oral CCI-779 daily total 8 week . - Arm II : Patients receive high dose CCI-779 arm I . - Arm III : Patients receive high dose ( high arm II ) CCI-779 arm I . Approximately 24-48 hour last dose CCI-779 , patient arm undergo radical prostatectomy . Patients follow day 7-10 4 week study completion . PROJECTED ACCRUAL : A total 40 patient ( 5 arm I II 30 arm III ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Diagnosis base minimum 6 core biopsy sample Clinically confirm organconfined disease Candidate radical prostatectomy No evidence metastatic disease CT scan bone scan High risk relapse base either follow criterion : Any one following : Stage T2C high Gleason score great 7 Prostatespecific antigen ( PSA ) great 20 ng/mL OR Any two following : Gleason score least 7 PSA 1020 ng/mL Greater 50 % total biopsy core cancer involvement PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic No active bleed Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic No acute chronic hepatitis B Hepatitis B surface antigen negative No acute chronic hepatitis C No antibody hepatitis C Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2 time ULN Renal No ongoing urinary tract infection necessitate rapid emergent surgical resection Creatinine great 1.5 time ULN Cardiovascular No unstable angina No myocardial infarction within past 6 month No lifethreatening ventricular arrhythmia require ongoing maintenance therapy Pulmonary No known pulmonary hypertension No pneumonitis Other Fertile patient must use effective contraception 12 week study participation HIV negative No severe immunocompromised state No active infection require antibiotic therapy No serious concurrent illness No major illness would substantially increase risk associate study participation No malignancy within past 5 year except basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy More 3 week since prior IV corticosteroids No concurrent systemic corticosteroid No prior concurrent hormonal therapy underlie malignancy Radiotherapy No prior concurrent radiotherapy Surgery More 3 month since prior major surgery Other More 1 month since prior experimental drug More 3 week since prior immunosuppressive agent No concurrent immunosuppressive therapy No concurrent investigational agent No concurrent enzymeinducing anticonvulsant ( e.g. , phenobarbital , phenytoin , carbamazepine ) No concurrent ketoconazole , diltiazem , rifampin , terfenadine , cisapride , astemizole , pimozide , Hypericum perforatum ( St. John 's wort ) No concurrent grapefruit grapefruit juice</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
</DOC>